Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

China Biotech’s Hong Kong IPO to Raise Up to $2 Billion

publication date: Nov 8, 2011
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
China National Biotechnology Group (CNBG) will raise as much as $2 billion in a Hong Kong IPO, an event that is expected to take place in the first half of next year. China National Biotech is the largest biotechnology company in China, producing a long list of vaccines and blood products. Reportedly, the company will change its name to China Biotechnology Co. China Biotech is a subsidiary of China National Pharmaceutical Group (also known as SinoPharm Group). More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...